Detalles de la búsqueda
1.
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
BMC Cancer
; 23(1): 1080, 2023 Nov 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37946136
2.
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
Breast Cancer Res
; 24(1): 80, 2022 11 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36401316
3.
Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience.
Cancers (Basel)
; 16(2)2024 Jan 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38254771
4.
Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
JAMA Netw Open
; 7(4): e244435, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38568692
5.
Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS.
STAR Protoc
; 4(1): 101951, 2023 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36856770
6.
Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.
Cancers (Basel)
; 15(4)2023 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36831640
7.
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era.
Cells
; 11(5)2022 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35269392
8.
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
Oncoimmunology
; 11(1): 2120676, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36117524
9.
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.
NPJ Breast Cancer
; 8(1): 28, 2022 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35246547
10.
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Cancers (Basel)
; 14(7)2022 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35406523
11.
Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives.
Cancers (Basel)
; 13(23)2021 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34885109
12.
Utility of exome sequencing in routine care for metastatic colorectal cancer.
Mol Clin Oncol
; 15(5): 229, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34631054
13.
Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer.
Cancers (Basel)
; 13(12)2021 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34208673
14.
Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.
Oncoimmunology
; 10(1): 1957603, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34377595
15.
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.
Thromb Res
; 205: 29-39, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34246011
16.
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Lung Cancer
; 136: 109-114, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31491676
Resultados
1 -
16
de 16
1
Próxima >
>>